Immunovia AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.05.21	CEO Patrik Dahlen purchases Immunovia shares (PR Newswire)
28.05.21	CEO Patrik Dahlen purchases Immunovia shares (PR Newswire)
27.05.21	Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™ PanCan-d (PR Newswire)
27.05.21	Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™ PanCan-d (PR Newswire)
12.05.21	Member of Immunovia's Board of Directors purchases shares in the company (PR Newswire)
12.05.21	Member of Immunovia's Board of Directors purchases shares in the company (PR Newswire)
07.05.21	Annual General Meeting - Immunovia AB (PR Newswire)
07.05.21	Annual General Meeting - Immunovia AB (PR Newswire)
04.05.21	Members of Immunovia's Board of Directors purchase shares in the company (PR Newswire)
04.05.21	Members of Immunovia's Board of Directors purchase shares in the company (PR Newswire)
28.04.21	Immunovia Reports Interim Report January - March 2021 (PR Newswire)
28.04.21	Immunovia Reports Interim Report January - March 2021 (PR Newswire)
22.04.21	Immunovia reiterates its road to reimbursement for the IMMray™ PanCan-d test (PR Newswire)
22.04.21	Immunovia reiterates its road to reimbursement for the IMMray™ PanCan-d test (PR Newswire)
21.04.21	Immunovia presents update on US market size for IMMray™ PanCan-d in the familial/hereditary risk group (PR Newswire)
21.04.21	Immunovia presents update on US market size for IMMray™ PanCan-d in the familial/hereditary risk group (PR Newswire)
21.04.21	Invitation to Presentation of Immunovia's Interim Report January - March 2021 (PR Newswire)
21.04.21	Invitation to Presentation of Immunovia's Interim Report January - March 2021 (PR Newswire)
16.04.21	IMMray™ PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network (PR Newswire)
16.04.21	IMMray™ PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network (PR Newswire)
30.03.21	Immunovia reports improved test performance of IMMrayTM PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients (PR Newswire)
30.03.21	Immunovia reports improved test performance of IMMrayTM PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients (PR Newswire)
30.03.21	Immunovia reports positive results of the blinded clinical validation of IMMray™ PanCan-d blood test in USA (PR Newswire)
30.03.21	Immunovia reports positive results of the blinded clinical validation of IMMray™ PanCan-d blood test in USA (PR Newswire)
12.03.21	Immunovia publishes the annual report for the financial year 2020 (PR Newswire)
12.03.21	Immunovia publishes the annual report for the financial year 2020 (PR Newswire)
26.02.21	Immunovia publishes data sets on the Optimization Study and Commercial Test Model Study (PR Newswire)
26.02.21	Immunovia publishes data sets on the Optimization Study and Commercial Test Model Study (PR Newswire)
17.02.21	Immunovia Full Year Report 2020 (PR Newswire)
17.02.21	Immunovia Full Year Report 2020 (PR Newswire)
15.02.21	Immunovia's PanFAM-1 Prospective Study Gathers Over 3000 Familial Hereditary Pancreatic Cancer Risk Samples And Will Be Analysed In The Second Half Of 2021 (PR Newswire)
15.02.21	Immunovia's PanFAM-1 Prospective Study Gathers Over 3000 Familial Hereditary Pancreatic Cancer Risk Samples And Will Be Analysed In The Second Half Of 2021 (PR Newswire)
11.02.21	Invitation to presentation of Immunovia's Full Year Report 2020 on February 17, 2021 (PR Newswire)
11.02.21	Invitation to presentation of Immunovia's Full Year Report 2020 on February 17, 2021 (PR Newswire)
10.02.21	Immunovia On Track For IMMray™ PanCan-d Sales Start In Q1 2021 (PR Newswire)
10.02.21	Immunovia On Track For IMMray™ PanCan-d Sales Start In Q1 2021 (PR Newswire)
19.01.21	Chief Executive Officer, Patrik Dahlen Buys Immunovia Warrants (PR Newswire)
19.01.21	Chief Executive Officer, Patrik Dahlen Buys Immunovia Warrants (PR Newswire)
07.01.21	Proteomic data derived from Immunovia's IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases (PR Newswire)
07.01.21	Proteomic data derived from Immunovia's IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases (PR Newswire)
14.12.20	Immunovia publishes link to Webinar No. 3 on IMMray™ PanCan-d: Verification Study and Clinical Use (PR Newswire)
14.12.20	Immunovia publishes link to Webinar No. 3 on IMMray™ PanCan-d: Verification Study and Clinical Use (PR Newswire)
11.12.20	Immunovia to Host a Third Webinar in the Series on IMMray™ PanCan-d: Verification Study and Clinical Use (PR Newswire)
11.12.20	Immunovia to Host a Third Webinar in the Series on IMMray™ PanCan-d: Verification Study and Clinical Use (PR Newswire)
07.12.20	Immunovia Announces Investor Relations Changes (PR Newswire)
07.12.20	Immunovia Announces Investor Relations Changes (PR Newswire)
03.12.20	Members of Immunovia's Board of Directors purchase shares in the company (PR Newswire)
03.12.20	Members of Immunovia's Board of Directors purchase shares in the company (PR Newswire)
02.12.20	Invitation to telephone conference in response to Dagens Industri's article published on December 1 (PR Newswire)
02.12.20	Invitation to telephone conference in response to Dagens Industri's article published on December 1 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Immunovia AB

Aktien Top/Flop

Meistgelesene Nachrichten